Genotype and Subtype Mapping of the Hepatitis C Virus
Starting soon
Conditions studied: Hepatitis C Virus, Mutation Abnormality, RNA Positive, Unusual Subtype, Resistance
In brief
Chronic hepatitis C virus (HCV) infection is the second leading cause of primary liver cancer worldwide and the leading cause in the United States. In 2020, an estimate 260,000 deaths were attributable to HCV globally, nearly 80,000 of which occurred in Europe, mainly due to complications such as cirrhosis or hepatocellular carcinoma (HCC). The CARTO-VHC study is a retrospective, observational, multicenter study based on data and samples collected during routine care from 2023 to 2024. The study does not involve direct human participation. The study aims to describe the different genotypes and subtypes of the hepatitis C virus, including unusual subtypes, in a large population of newly diagnosed HCV-positive patients. This will help identify the most common types circulating in France. Additionally, the study will provide a comprehensive understanding of therapeutic failures and drug resistance to direct-acting antivirals (DAA) in treated patients.
Key facts
- Study ID
- NCT07503288
- Run by
- Assistance Publique - Hôpitaux de Paris
- People needed
- 2500
- Starts
- 2026-06-01
- Expected to finish
- 2029-03-01
- Last updated by the study team
- 2026-05-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patient aged 18 years old or more
- Newly diagnosed patient positive for HCV (presence of HCV antibodies)
- Patient with active infection (HCV RNA > 0)
You may not qualify if…
- Patients who decline to participate in the study and oppose the use of their personal data
- Patients under legal protection (guardianship or curatorship)
Where it is running
- AP-HP Henri Mondor — Créteil, France
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.